Current issues in initiation of antiretroviral therapy

Meg C. Doherty, Joel E. Gallant

Research output: Contribution to journalArticlepeer-review


Initial therapy for patients with HIV infection is becoming increasingly simple and well tolerated. Effective and durable therapy can now be achieved with a regimen that consists of just 2 pills dosed once a day without food restrictions, and it is anticipated that we will soon have a potent HAART regimen contained in a single pill. Therapy - including the decision of when to start - must always be individualized to maximize the likelihood of a durable response. Published guidelines agree that therapy should be started for any patient with symptomatic disease or AIDS and for asymptomatic patients with CD4+ cell counts below 200/μL, but there is an increasingly strong rationale for earlier initiation of therapy. Preferred starting regimens include either a nonnucleoside reverse transcriptase inhibitor or a protease inhibitor as an "anchor drug," combined with 2 nucleoside analogs.

Original languageEnglish (US)
Pages (from-to)599-615
Number of pages17
JournalInfections in Medicine
Issue number12
StatePublished - Dec 1 2005


  • AIDS
  • Antiretroviral therapy
  • HIV

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Current issues in initiation of antiretroviral therapy'. Together they form a unique fingerprint.

Cite this